169 related articles for article (PubMed ID: 19025415)
61. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
[TBL] [Abstract][Full Text] [Related]
62. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
63. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes.
Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F
Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501
[TBL] [Abstract][Full Text] [Related]
64. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.
Guest RD; Hawkins RE; Kirillova N; Cheadle EJ; Arnold J; O'Neill A; Irlam J; Chester KA; Kemshead JT; Shaw DM; Embleton MJ; Stern PL; Gilham DE
J Immunother; 2005; 28(3):203-11. PubMed ID: 15838376
[TBL] [Abstract][Full Text] [Related]
65. CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.
Wang X; Wong CW; Urak R; Mardiros A; Budde LE; Chang WC; Thomas SH; Brown CE; La Rosa C; Diamond DJ; Jensen MC; Nakamura R; Zaia JA; Forman SJ
Clin Cancer Res; 2015 Jul; 21(13):2993-3002. PubMed ID: 25838392
[TBL] [Abstract][Full Text] [Related]
66. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
Xu Y; Zhang M; Ramos CA; Durett A; Liu E; Dakhova O; Liu H; Creighton CJ; Gee AP; Heslop HE; Rooney CM; Savoldo B; Dotti G
Blood; 2014 Jun; 123(24):3750-9. PubMed ID: 24782509
[TBL] [Abstract][Full Text] [Related]
67. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
68. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.
Boissel L; Betancur M; Lu W; Wels WS; Marino T; Van Etten RA; Klingemann H
Leuk Lymphoma; 2012 May; 53(5):958-65. PubMed ID: 22023526
[TBL] [Abstract][Full Text] [Related]
69. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
70. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
71. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
72. GITR domain inside CAR co-stimulates activity of CAR-T cells against cancer.
Golubovskaya VM; Berahovich R; Xu Q; Zhou H; Xu S; Guan J; Harto H; Li L; Wu L
Front Biosci (Landmark Ed); 2018 Jun; 23(12):2245-2254. PubMed ID: 29772559
[TBL] [Abstract][Full Text] [Related]
73. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
74. Simplified process for the production of anti-CD19-CAR-engineered T cells.
Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
[TBL] [Abstract][Full Text] [Related]
75. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.
Qin H; Edwards JP; Zaritskaya L; Gupta A; Mu CJ; Fry TJ; Hilbert DM; LaFleur DW
Mol Ther; 2019 Jul; 27(7):1262-1274. PubMed ID: 31043341
[TBL] [Abstract][Full Text] [Related]
76. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
77. Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.
Cheng Y; Zheng X; Wang X; Chen Y; Wei H; Sun R; Tian Z; Sun H
Cancer Biol Med; 2020 Nov; 17(4):1026-1038. PubMed ID: 33299651
[TBL] [Abstract][Full Text] [Related]
78. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Boice M; Salloum D; Mourcin F; Sanghvi V; Amin R; Oricchio E; Jiang M; Mottok A; Denis-Lagache N; Ciriello G; Tam W; Teruya-Feldstein J; de Stanchina E; Chan WC; Malek SN; Ennishi D; Brentjens RJ; Gascoyne RD; Cogné M; Tarte K; Wendel HG
Cell; 2016 Oct; 167(2):405-418.e13. PubMed ID: 27693350
[TBL] [Abstract][Full Text] [Related]
79. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.
De Oliveira SN; Wang J; Ryan C; Morrison SL; Kohn DB; Hollis RP
J Transl Med; 2013 Jan; 11():23. PubMed ID: 23360526
[TBL] [Abstract][Full Text] [Related]
80. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC
Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
